« Back European Neuropsychopharmacology

Article in Press

Characterization of the neuropsychological phenotype of glycine N-methyltransferase−/− mice and evaluation of its responses to clozapine and sarcosine treatments

  • Ching-Ping Yang

      Affiliations

    • Institute of Public Health, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Hsiang-An Wang

      Affiliations

    • AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Tung-Hu Tsai

      Affiliations

    • Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Angela Fan

      Affiliations

    • Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Chia-Lang Hsu

      Affiliations

    • Institute of Biomedical Informatics, School of Medicine, National Yang-Ming University, Taipei, Taiwan
    • ,
  • Chun-Jung Chen

      Affiliations

    • Department of Education and Research, Taichung Veterans General Hospital, Taichung, Taiwan
    • ,
  • Chen-Jee Hong

      Affiliations

    • Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan
    • Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan
    • Brain Research Center, National Yang‐Ming University, Taipei, Taiwan
    • ,
  • Yi-Ming Arthur Chen

      Affiliations

    • AIDS Prevention and Research Center, National Yang-Ming University, Taipei, Taiwan
    • Department of Microbiology, School of Medicine, National Yang‐Ming University, Taipei, Taiwan
    • Brain Research Center, National Yang‐Ming University, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author at: Department of Microbiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.

Received 17 June 2011 ,Revised 29 November 2011 ,Accepted 16 December 2011. Published online 24 January 2012 Corrected Proof

References 

  1. Bergeron F, Otto A, Blache P, Day R, Denoroy L, Brandsch R, et al. Molecular cloning and tissue distribution of rat sarcosine dehydrogenase. Eur. J. Biochem. 1998;257:556–561
  2. Bjarnadottir M, Misner DL, Haverfield-Gross S, Bruun S, Helgason VG, Stefansson H, et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/− knock-outs compared with wild-type mice. J. Neurosci. 2007;27:4519–4529
  3. Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl.). 2009;202:385–396
  4. Blumenstein J, Williams GR. The enzymic N-methylation of glycine. Biochem. Biophys. Res. Commun. 1960;3:259–263
  5. Bork P, Ouzounis C, Sander C, Scharf M, Schneider R, Sonnhammer E. Comprehensive sequence analysis of the 182 predicted open reading frames of yeast chromosome III. Protein Sci. 1992;1:1677–1690
  6. Boulay D, Bergis O, Avenet P, Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology. 2010;35:416–427
  7. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry. 1990;47:181–188
  8. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl.). 2001;156:234–258
  9. Bullock AE, Slobe BS, Vazquez V, Collins AC. Inbred mouse strains differ in the regulation of startle and prepulse inhibition of the startle response. Behav. Neurosci. 1997;111:1353–1360
  10. Butterworth RF. Hepatic encephalopathy. Alcohol Res. Health. 2003;27:240–246
  11. Chen YM, Chen LY, Wong FH, Lee CM, Chang TJ, Yang-Feng TL. Genomic structure, expression, and chromosomal localization of the human glycine N-methyltransferase gene. Genomics. 2000;66:43–47
  12. Chen YJ, Johnson MA, Lieberman MD, Goodchild RE, Schobel S, Lewandowski N, et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J. Neurosci. 2008;28:6872–6883
  13. Cook RJ, Wagner C. Glycine N-methyltransferase is a folate binding protein of rat liver cytosol. Proc. Natl. Acad. Sci. U. S. A. 1984;81:3631–3634
  14. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 2006;26:365–384
  15. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005;29:571–625
  16. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 2004;36:131–137
  17. Feng J, Zhou Y, Campbell SL, Le T, Li E, Sweatt JD, et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat. Neurosci. 2010;13:423–430
  18. Freedman R. Schizophrenia. N. Engl. J. Med. 2003;349:1738–1749
  19. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry. 2003;160:636–645
  20. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat. Med. 2006;12:824–828
  21. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol. Psychiatry. 2006;60:132–140
  22. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch. Gen. Psychiatry. 2003;60:572–576
  23. Hong LE, Wonodi I, Stine OC, Mitchell BD, Thaker GK. Evidence of missense mutations on the neuregulin 1 gene affecting function of prepulse inhibition. Biol. Psychiatry. 2008;63:17–23
  24. Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, et al. Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. Neuron. 2000;26:443–455
  25. Huang YC, Lee CM, Chen M, Chung MY, Chang YH, Huang WJ, et al. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin. Cancer Res. 2007;13:1412–1420
  26. Jones CA, Watson DJ, Fone K. Animal models of schizophrenia. Br. J. Pharmacol. 2011;164:1162–1194
  27. Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci. 2010;31:381–390
  28. Kerr SJ. Competing methyltransferase systems. J. Biol. Chem. 1972;247:4248–4252
  29. Lai MC, Yang DR, Chuang MJ. Regulatory factors associated with synthesis of the osmolyte glycine betaine in the halophilic methanoarchaeon Methanohalophilus portucalensis. Appl. Environ. Microbiol. 1999;65:828–833
  30. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry. 2005;62:1196–1204
  31. Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry. 2006;60:645–649
  32. Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int. J. Neuropsychopharmacol. 2010;13:451–460
  33. LaPlant Q, Vialou V, Covington HE, Dumitriu D, Feng J, Warren BL, et al. Dnmt3a regulates emotional behavior and spine plasticity in the nucleus accumbens. Nat. Neurosci. 2010;13:1137–1143
  34. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron. 2000;28:325–334
  35. Liao YJ, Liu SP, Lee CM, Yen CH, Chuang PC, Chen CY, et al. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer. 2009;124:816–826
  36. Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, et al. Glycine N-methyltransferase−/− mice develop chronic hepatitis and glycogen storage disease in the liver. Hepatology. 2007;46:1413–1425
  37. Liu Y, Xu F, Zeng X, Yang L, Deng Y, Wu Z, et al. Application of a liquid chromatography/tandem mass spectrometry method to pharmacokinetic study of mangiferin in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010;878:3345–3350
  38. Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM. Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J. Hepatol. 2009;51:528–534
  39. Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, Martinez N, Varela M, Luka Z, et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology. 2008;47:1191–1199
  40. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat. Rev. Neurosci. 2008;9:437–452
  41. Michitaka K, Tokumoto Y, Uesugi K, Kisaka Y, Hirooka M, Konishi I, et al. Neuropsychiatric dysfunction in patients with chronic hepatitis and liver cirrhosis. Hepatol. Res. 2008;38:1069–1075
  42. Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 2009;5:e1000373
  43. Ogawa H, Gomi T, Fujioka M. Mammalian glycine N-methyltransferases. Comparative kinetic and structural properties of the enzymes from human, rat, rabbit and pig livers. Comp. Biochem. Physiol. B. 1993;106:601–611
  44. Paylor R, Crawley JN. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl.). 1997;132:169–180
  45. Sei Y, Ren-Patterson R, Li Z, Tunbridge EM, Egan MF, Kolachana BS, et al. Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Mol. Psychiatry. 2007;12:946–957
  46. Seshadri S, Kamiya A, Yokota Y, Prikulis I, Kano S, Hayashi-Takagi A, et al. Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc. Natl. Acad. Sci. U. S. A. 2010;107:5622–5627
  47. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl.). 1985;85:367–370
  48. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry. 2003;60:1187–1192
  49. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J. Neurol. Neurosurg. Psychiatry. 1995;58:192–200
  50. Thiselton DL, Vladimirov VI, Kuo PH, McClay J, Wormley B, Fanous A, et al. AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry. 2008;63:449–457
  51. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 2004;55:452–456
  52. Tseng TL, Shih YP, Huang YC, Wang CK, Chen PH, Chang JG, et al. Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. Cancer Res. 2003;63:647–654
  53. Wang Q, Liu L, Pei L, Ju W, Ahmadian G, Lu J, et al. Control of synaptic strength, a novel function of Akt. Neuron. 2003;38:915–928
  54. Wang X, Li W, Parra JL, Beugnet A, Proud CG. The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol. Cell. Biol. 2003;23:1546–1557
  55. Willott JF, Tanner L, O'Steen J, Johnson KR, Bogue MA, Gagnon L. Acoustic startle and prepulse inhibition in 40 inbred strains of mice. Behav. Neurosci. 2003;117:716–727
  56. Yang SY, Hong CJ, Huang YH, Tsai SJ. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci. Lett. 2010;469:127–130
  57. Yen, C.H., Lu, Y.C., Li, Y.C., Lee, M.C., Chen, C.Y., Cheng, M.Y., Hung, S.F., Chen, K.F., Cheng, A.L., Liao, L.Y., Lee, Y.H., Chen, Y.M., in press. Functional Characterization of GNMT and its Interacting Protein-DEPTOR in Hepatocellular Carcinoma. Mol. Med. (Electronic publication ahead of print). doi:10.2119/molmed.2011.00331.
  58. Yeo EJ, Wagner C. Tissue distribution of glycine N-methyltransferase, a major folate-binding protein of liver. Proc. Natl. Acad. Sci. U. S. A. 1994;91:210–214
  59. Yoon SC, Seo MS, Kim SH, Jeon WJ, Ahn YM, Kang UG, et al. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex. Neurosci. Lett. 2008;434:23–28
  60. Yoshii A, Constantine-Paton M. BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation. Nat. Neurosci. 2007;10:702–711

☆ Competing interests: The authors declared that there was no conflict of interests.

PII: S0924-977X(11)00334-8

doi: 10.1016/j.euroneuro.2011.12.007

« Back European Neuropsychopharmacology

Article in Press

Article Tools

* Image Usage & Resolution